In a report released today, Justin Keywood from Stifel Nicolaus upgraded CareRx to a Buy, with a price target of C$4.50. The company’s shares cl...
In a report released today, Justin Keywood from Stifel Nicolaus upgraded CareRx to a Buy, with a price target of C$4.50. The company’s shares cl...